Abstract
The last major advance in HIV therapeutics came in 2007–08 with the approval of raltegravir, the first integrase strand transfer inhibitor (INSTI).1 Second generation INSTIs, dolutegravir and bictegravir, with longer half-lives and with a higher barrier to resistance in single tablet regimens have cemented this class of antiretrovirals as the preferred anchor drugs in first-line HIV therapy worldwide.2,3
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
